[{"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-001", "question": "A 74-year-old man presents with heart failure with preserved ejection fraction (HFpEF) and bilateral carpal tunnel syndrome. Echocardiography reveals a granular 'sparkling' appearance of the myocardium and increased wall thickness. A technetium-99m pyrophosphate (PYP) scan shows Grade 3 cardiac uptake (uptake > rib uptake). Serum immunofixation reveals a small IgG lambda monoclonal protein, and serum free light chain ratio is 1.8. Which of the following is the most appropriate next step in management to confirm the diagnosis?", "options": ["Initiate tafamidis therapy", "Perform TTR genetic testing", "Endomyocardial biopsy", "Abdominal fat pad aspiration", "Initiate bortezomib, cyclophosphamide, and dexamethasone"], "answer": "C", "answer_index": 2, "explanation": "While Grade 2/3 PYP uptake is highly specific for ATTR cardiac amyloidosis, this specificity drops significantly in the presence of a monoclonal gammopathy (MGUS). AL amyloidosis can occasionally show uptake on PYP scans. Therefore, in a patient with a positive PYP scan AND a monoclonal protein, a tissue biopsy (endomyocardial is gold standard if non-cardiac biopsy is negative or to avoid sampling error) is mandatory to distinguish ATTR from AL amyloidosis before starting treatment.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Elderly man with HFpEF, bilateral carpal tunnel, echo with granular/sparkling myocardium and increased wall thickness, PYP scan with Grade 3 uptake (classically highly suggestive of ATTR), but presence of a small IgG lambda monoclonal protein and mildly abnormal free light chain ratio. The question asks for the most appropriate next step to confirm the diagnosis.\\nGiven that PYP Grade 2–3 uptake is not fully specific for ATTR in the setting of a monoclonal gammopathy, current guidance is that tissue confirmation with amyloid typing is required to distinguish ATTR from AL, with endomyocardial biopsy being the gold standard when cardiac involvement is central or when non-cardiac sites may miss disease. Thus, C (endomyocardial biopsy) is the best answer.\\nAlternatives: A and E are treatment steps before definitive typing; B (TTR genetic testing) is for subtype characterization after ATTR is confirmed; D (fat pad) is reasonable but less sensitive for ATTR and not the gold-standard cardiac confirmation implied by the stem.\\nMain medical accuracy issues: None significant; explanation aligns with contemporary consensus.\\nMinimal fix: Clarify in stem that non-cardiac biopsy has not yet been attempted if wanting to preclude D from being seen as equally reasonable.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Elderly man with HFpEF, bilateral carpal tunnel, echo with granular/sparkling myocardium and increased wall thickness, PYP scan with Grade 3 uptake (classically highly suggestive of ATTR), but presence of a small IgG lambda monoclonal protein and mildly abnormal free light chain ratio. The question asks for the most appropriate next step to confirm the diagnosis.\nGiven that PYP Grade 2–3 uptake is not fully specific for ATTR in the setting of a monoclonal gammopathy, current guidance is that tissue confirmation with amyloid typing is required to distinguish ATTR from AL, with endomyocardial biopsy being the gold standard when cardiac involvement is central or when non-cardiac sites may miss disease. Thus, C (endomyocardial biopsy) is the best answer.\nAlternatives: A and E are treatment steps before definitive typing; B (TTR genetic testing) is for subtype characterization after ATTR is confirmed; D (fat pad) is reasonable but less sensitive for ATTR and not the gold-standard cardiac confirmation implied by the stem.\nMain medical accuracy issues: None significant; explanation aligns with contemporary consensus.\nMinimal fix: Clarify in stem that non-cardiac biopsy has not yet been attempted if wanting to preclude D from being seen as equally reasonable.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-002", "question": "A 24-year-old male presents with recurrent fevers, livedo racemosa, and acute left hemiparesis. MRI shows a lacunar infarct in the internal capsule. Angiography reveals a 'beads-on-a-string' appearance in the mesenteric and renal arteries. Laboratory evaluation shows low serum IgM and IgG levels. Genetic testing confirms a biallelic loss-of-function mutation in ADA2. Which of the following is the most appropriate maintenance therapy?", "options": ["Cyclophosphamide", "Rituximab", "Etanercept", "Prednisone monotherapy", "Plasma exchange"], "answer": "C", "answer_index": 2, "explanation": "The patient has Deficiency of Adenosine Deaminase 2 (DADA2), which mimics Polyarteritis Nodosa (PAN) but is distinct due to its association with early-onset strokes and hypogammaglobulinemia. Unlike classic PAN, which is treated with cyclophosphamide, DADA2 is driven by TNF-alpha dysregulation. TNF inhibitors (like etanercept) are the treatment of choice and are highly effective in preventing recurrent strokes, whereas cyclophosphamide is often ineffective.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Young adult with recurrent fevers, livedo racemosa, PAN-like medium-vessel vasculopathy with “beads-on-a-string” in mesenteric/renal arteries, early lacunar stroke, hypogammaglobulinemia, and confirmed biallelic ADA2 loss-of-function mutation. This is classic Deficiency of Adenosine Deaminase 2 (DADA2). Current consensus is that DADA2 is driven by TNF-mediated inflammation and that TNF inhibitors are first-line for maintenance to prevent recurrent strokes and systemic vasculitis.\\nEvaluation of alternatives: Cyclophosphamide (A) is standard for classic PAN but often ineffective in DADA2; stem explicitly distinguishes this. Rituximab (B) targets B cells and is not established as primary therapy in DADA2. Prednisone monotherapy (D) is inadequate for long-term prevention and disease control. Plasma exchange (E) is not standard for maintenance in this genetic TNF-driven vasculitis.\\nMain logical/medical issues: None significant; stem gives a confirmed genetic diagnosis and describes the pathognomonic features, making TNF inhibition uniquely best.\\nMinimal fix: Option C could be phrased generically as “TNF-α inhibitor therapy (e.g., etanercept)” to emphasize the class rather than a single agent, but this is not required for validity or accuracy.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Young adult with recurrent fevers, livedo racemosa, PAN-like medium-vessel vasculopathy with “beads-on-a-string” in mesenteric/renal arteries, early lacunar stroke, hypogammaglobulinemia, and confirmed biallelic ADA2 loss-of-function mutation. This is classic Deficiency of Adenosine Deaminase 2 (DADA2). Current consensus is that DADA2 is driven by TNF-mediated inflammation and that TNF inhibitors are first-line for maintenance to prevent recurrent strokes and systemic vasculitis.\nEvaluation of alternatives: Cyclophosphamide (A) is standard for classic PAN but often ineffective in DADA2; stem explicitly distinguishes this. Rituximab (B) targets B cells and is not established as primary therapy in DADA2. Prednisone monotherapy (D) is inadequate for long-term prevention and disease control. Plasma exchange (E) is not standard for maintenance in this genetic TNF-driven vasculitis.\nMain logical/medical issues: None significant; stem gives a confirmed genetic diagnosis and describes the pathognomonic features, making TNF inhibition uniquely best.\nMinimal fix: Option C could be phrased generically as “TNF-α inhibitor therapy (e.g., etanercept)” to emphasize the class rather than a single agent, but this is not required for validity or accuracy.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-003", "question": "A 64-year-old male presents with a 1-year history of progressive gait instability, dysarthria, and dysphagia. His wife reports he has severe insomnia, stridor during sleep, and acts out his dreams. Polysomnography confirms obstructive sleep apnea and complex behaviors during both REM and NREM sleep. MRI brain is unremarkable. Which of the following antibodies is most likely to be positive?", "options": ["Anti-Hu", "Anti-Ma2", "Anti-LGI1", "Anti-IgLON5", "Anti-DPPX"], "answer": "D", "answer_index": 3, "explanation": "Anti-IgLON5 disease is a distinct tauopathy characterized by a unique sleep disorder (parasomnias in both REM and NREM sleep, stridor, OSA) combined with bulbar dysfunction and gait instability. While Anti-Ma2 is associated with brainstem/diencephalic involvement and sleepiness, the specific combination of stridor, NREM parasomnias, and bulbar palsy is pathognomonic for Anti-IgLON5.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Older adult (64 years) with 1-year progressive gait instability, dysarthria, dysphagia (bulbar involvement), severe insomnia, sleep stridor, acts out dreams; polysomnography shows obstructive sleep apnea plus complex parasomnias in both REM and NREM sleep; MRI is unremarkable. This constellation—mixed REM/NREM parasomnias, stridor, OSA, and bulbar/gait dysfunction with normal MRI—is highly characteristic of anti-IgLON5 disease, a distinctive tauopathy.\\nEvaluation of alternatives: Anti-Hu typically causes paraneoplastic encephalomyelitis/sensory neuronopathy with cancer, not this sleep–bulbar pattern. Anti-Ma2 is associated with diencephalic/brainstem encephalitis and hypersomnia rather than complex NREM parasomnias and stridor. Anti-LGI1 produces limbic encephalitis and faciobrachial dystonic seizures, not this presentation. Anti-DPPX is linked to CNS hyperexcitability, diarrhea, and weight loss, not characteristic parasomnia/stridor.\\nMain logical issues: None; stem provides sufficient discriminatory sleep and bulbar features to identify a unique best antibody. No internal contradictions.\\nMain medical accuracy issues: The description of anti-IgLON5 disease and differentiation from Ma2 and others is consistent with current knowledge.\\nMinimal fix: None required; optionally add a malignancy history (negative) to further de-emphasize anti-Hu/Ma2 but this is not necessary for clarity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Older adult (64 years) with 1-year progressive gait instability, dysarthria, dysphagia (bulbar involvement), severe insomnia, sleep stridor, acts out dreams; polysomnography shows obstructive sleep apnea plus complex parasomnias in both REM and NREM sleep; MRI is unremarkable. This constellation—mixed REM/NREM parasomnias, stridor, OSA, and bulbar/gait dysfunction with normal MRI—is highly characteristic of anti-IgLON5 disease, a distinctive tauopathy.\nEvaluation of alternatives: Anti-Hu typically causes paraneoplastic encephalomyelitis/sensory neuronopathy with cancer, not this sleep–bulbar pattern. Anti-Ma2 is associated with diencephalic/brainstem encephalitis and hypersomnia rather than complex NREM parasomnias and stridor. Anti-LGI1 produces limbic encephalitis and faciobrachial dystonic seizures, not this presentation. Anti-DPPX is linked to CNS hyperexcitability, diarrhea, and weight loss, not characteristic parasomnia/stridor.\nMain logical issues: None; stem provides sufficient discriminatory sleep and bulbar features to identify a unique best antibody. No internal contradictions.\nMain medical accuracy issues: The description of anti-IgLON5 disease and differentiation from Ma2 and others is consistent with current knowledge.\nMinimal fix: None required; optionally add a malignancy history (negative) to further de-emphasize anti-Hu/Ma2 but this is not necessary for clarity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-004", "question": "A 68-year-old male presents with fever of unknown origin, 15 kg weight loss, and fatigue 4 years after undergoing aortic valve replacement. Labs reveal pancytopenia and elevated liver enzymes. TTE and TEE show no vegetations. PET-CT demonstrates hypermetabolic activity in the spleen and bone marrow. Bone marrow biopsy reveals non-caseating granulomas. Standard blood cultures are negative. Which of the following is the most likely etiology?", "options": ["Sarcoidosis", "Culture-negative endocarditis (HACEK group)", "Mycobacterium chimaera", "Tropheryma whipplei", "Late-onset prosthetic valve thrombosis"], "answer": "C", "answer_index": 2, "explanation": "This is the classic presentation of disseminated *Mycobacterium chimaera* infection associated with contaminated heater-cooler units used during cardiopulmonary bypass. The incubation period can be several years. It presents with systemic symptoms, cytopenias, and granulomatous inflammation (often misdiagnosed as sarcoidosis). Diagnosis requires specific mycobacterial blood cultures or tissue PCR.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Remote (4-year) history of aortic valve replacement with cardiopulmonary bypass; fever of unknown origin, marked weight loss, fatigue; pancytopenia and elevated liver enzymes; PET-CT showing hypermetabolic spleen and bone marrow; bone marrow with non-caseating granulomas; standard blood cultures negative. This constellation, especially post–cardiac surgery with granulomatous disease and negative routine cultures, strongly points to disseminated Mycobacterium chimaera from contaminated heater–cooler units.\\nOption analysis: Sarcoidosis (A) can cause non-caseating granulomas and cytopenias but is not specifically tied to prior cardiac surgery and would not be the single best etiology in this post–valve replacement context. Culture-negative endocarditis, HACEK (B), usually shows valvular vegetations and may have positive specialized cultures. T. whipplei (D) causes weight loss and systemic symptoms but typically involves malabsorption, arthralgias, PAS-positive macrophages rather than classic non-caseating granulomas. Late prosthetic valve thrombosis (E) doesn’t explain granulomatous marrow or FUO.\\nMain medical accuracy issues: None significant; description and rationale match current reports of M. chimaera outbreaks.\\nMinimal fix: Add an explicit mention of cardiopulmonary bypass with heater–cooler device during the valve surgery to tighten the association with M. chimaera.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Remote (4-year) history of aortic valve replacement with cardiopulmonary bypass; fever of unknown origin, marked weight loss, fatigue; pancytopenia and elevated liver enzymes; PET-CT showing hypermetabolic spleen and bone marrow; bone marrow with non-caseating granulomas; standard blood cultures negative. This constellation, especially post–cardiac surgery with granulomatous disease and negative routine cultures, strongly points to disseminated Mycobacterium chimaera from contaminated heater–cooler units.\nOption analysis: Sarcoidosis (A) can cause non-caseating granulomas and cytopenias but is not specifically tied to prior cardiac surgery and would not be the single best etiology in this post–valve replacement context. Culture-negative endocarditis, HACEK (B), usually shows valvular vegetations and may have positive specialized cultures. T. whipplei (D) causes weight loss and systemic symptoms but typically involves malabsorption, arthralgias, PAS-positive macrophages rather than classic non-caseating granulomas. Late prosthetic valve thrombosis (E) doesn’t explain granulomatous marrow or FUO.\nMain medical accuracy issues: None significant; description and rationale match current reports of M. chimaera outbreaks.\nMinimal fix: Add an explicit mention of cardiopulmonary bypass with heater–cooler device during the valve surgery to tighten the association with M. chimaera.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-005", "question": "A 31-year-old female presents with amenorrhea 4 months after a full-term delivery. Ultrasound reveals a 4 cm echogenic mass in the myometrium. Serum beta-hCG is 120 IU/L. Immunohistochemistry of a biopsy specimen shows diffuse positivity for human placental lactogen (hPL) and Ki-67 index of 15%. Staging workup is negative for metastasis. What is the treatment of choice?", "options": ["Methotrexate and Folinic Acid", "Actinomycin D", "EMA-CO regimen", "Hysterectomy", "Pembrolizumab"], "answer": "D", "answer_index": 3, "explanation": "The diagnosis is Placental Site Trophoblastic Tumor (PSTT), distinguished from choriocarcinoma by low beta-hCG, strong hPL positivity, and origin from intermediate trophoblasts. Unlike choriocarcinoma, PSTT is relatively resistant to chemotherapy. For localized (Stage I) disease, hysterectomy is the primary and definitive treatment. Chemotherapy is reserved for metastatic or high-risk disease.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Recent term pregnancy; 4-month postpartum amenorrhea; 4-cm myometrial mass; low but detectable β-hCG (120 IU/L); immunohistochemistry with diffuse hPL positivity and intermediate Ki-67; no metastasis. These findings are classic for placental site trophoblastic tumor (PSTT), which arises from intermediate trophoblasts, secretes low hCG but high hPL, and tends to be chemoresistant. For Stage I, uterus-confined PSTT, the recommended treatment is total hysterectomy, matching option D.\\nAssessment of alternatives: A (methotrexate + folinic acid), B (actinomycin D), and C (EMA-CO) are standard chemotherapy options for gestational trophoblastic neoplasia such as choriocarcinoma or high-risk GTN, but PSTT is relatively resistant, so these are not first-line in localized disease. E (pembrolizumab) is investigational/second-line and not standard first-line therapy for localized PSTT.\\nMain medical accuracy issue(s): None significant; the pathologic and management details are contemporary and accurate.\\nMinimal fix: Specify “total abdominal hysterectomy” in option D (or in stem) to clarify the surgical approach, but this is a minor wording issue and does not affect answer selection.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Recent term pregnancy; 4-month postpartum amenorrhea; 4-cm myometrial mass; low but detectable β-hCG (120 IU/L); immunohistochemistry with diffuse hPL positivity and intermediate Ki-67; no metastasis. These findings are classic for placental site trophoblastic tumor (PSTT), which arises from intermediate trophoblasts, secretes low hCG but high hPL, and tends to be chemoresistant. For Stage I, uterus-confined PSTT, the recommended treatment is total hysterectomy, matching option D.\nAssessment of alternatives: A (methotrexate + folinic acid), B (actinomycin D), and C (EMA-CO) are standard chemotherapy options for gestational trophoblastic neoplasia such as choriocarcinoma or high-risk GTN, but PSTT is relatively resistant, so these are not first-line in localized disease. E (pembrolizumab) is investigational/second-line and not standard first-line therapy for localized PSTT.\nMain medical accuracy issue(s): None significant; the pathologic and management details are contemporary and accurate.\nMinimal fix: Specify “total abdominal hysterectomy” in option D (or in stem) to clarify the surgical approach, but this is a minor wording issue and does not affect answer selection.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-006", "question": "A 40-year-old male with a known diagnosis of Brugada syndrome presents to the ER in electrical storm, having received 4 appropriate ICD shocks for ventricular fibrillation in the past hour. He is currently conscious but anxious. Vital signs are BP 110/70, HR 90. Which pharmacologic agent is most appropriate to suppress the arrhythmia?", "options": ["Intravenous Amiodarone", "Intravenous Lidocaine", "Intravenous Isoproterenol", "Intravenous Procainamide", "Intravenous Metoprolol"], "answer": "C", "answer_index": 2, "explanation": "In Brugada syndrome electrical storm, the goal is to decrease the ST-segment elevation and dispersion. Isoproterenol (a beta-agonist) increases heart rate and calcium current, normalizing the ST segment and suppressing VF. Quinidine is the oral alternative. Amiodarone, beta-blockers, and sodium channel blockers (Procainamide, Lidocaine) are contraindicated or ineffective as they can unmask or exacerbate the Brugada pattern.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Known Brugada syndrome; currently in electrical storm with multiple appropriate ICD shocks for ventricular fibrillation within 1 hour; hemodynamically stable (BP 110/70, HR 90); question asks for most appropriate pharmacologic agent to suppress arrhythmia. In Brugada electrical storm, catecholamine infusion (isoproterenol) is a recognized acute therapy to reduce ST elevation and phase 2 reentry by increasing heart rate and calcium current. This makes IV isoproterenol (C) the single best choice.\\nCompeting options: Amiodarone (A) and beta-blockers (E) are generally ineffective/possibly harmful in Brugada electrical storm and may exacerbate arrhythmogenic substrate. Lidocaine (B) and procainamide (D) are sodium channel blockers and can worsen the Brugada ECG pattern and arrhythmias. Thus all alternatives are inferior or contraindicated based on current understanding.\\nMain logical issues: None; the clinical context clearly points to Brugada-specific management and options are well separated.\\nMain medical accuracy issues: None significant; explanation is consistent with contemporary consensus (isoproterenol for acute electrical storm; quinidine as oral alternative).\\nMinimal fix: Optionally specify that isoproterenol is given as a continuous IV infusion for electrical storm suppression to add clarity.\",\n  \"medical_accuracy_score\": \n\n     \"5\",\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Known Brugada syndrome; currently in electrical storm with multiple appropriate ICD shocks for ventricular fibrillation within 1 hour; hemodynamically stable (BP 110/70, HR 90); question asks for most appropriate pharmacologic agent to suppress arrhythmia. In Brugada electrical storm, catecholamine infusion (isoproterenol) is a recognized acute therapy to reduce ST elevation and phase 2 reentry by increasing heart rate and calcium current. This makes IV isoproterenol (C) the single best choice.\nCompeting options: Amiodarone (A) and beta-blockers (E) are generally ineffective/possibly harmful in Brugada electrical storm and may exacerbate arrhythmogenic substrate. Lidocaine (B) and procainamide (D) are sodium channel blockers and can worsen the Brugada ECG pattern and arrhythmias. Thus all alternatives are inferior or contraindicated based on current understanding.\nMain logical issues: None; the clinical context clearly points to Brugada-specific management and options are well separated.\nMain medical accuracy issues: None significant; explanation is consistent with contemporary consensus (isoproterenol for acute electrical storm; quinidine as oral alternative).\nMinimal fix: Optionally specify that isoproterenol is given as a continuous IV infusion for electrical storm suppression to add clarity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-007", "question": "A 32-year-old female presents with subacute confusion, bilateral hearing loss, and visual field deficits. MRI brain shows multiple T2 hyperintense lesions in the corpus callosum ('snowballs') and periventricular white matter. Fluorescein angiography reveals multiple branch retinal artery occlusions (BRAO). CSF shows mild pleocytosis and elevated protein but no oligoclonal bands. What is the most likely diagnosis?", "options": ["Multiple Sclerosis", "CADASIL", "Susac Syndrome", "Primary CNS Angiitis", "Mitochondrial Encephalomyopathy (MELAS)"], "answer": "C", "answer_index": 2, "explanation": "Susac Syndrome is a rare autoimmune endotheliopathy characterized by the clinical triad of encephalopathy, branch retinal artery occlusions (BRAO), and sensorineural hearing loss. The MRI finding of 'snowball' lesions in the corpus callosum is highly characteristic. It is often misdiagnosed as MS, but the presence of BRAO and callosal lesions (rather than callososeptal interface lesions) distinguishes it.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Subacute encephalopathy/confusion, bilateral hearing loss, visual field deficits; MRI with multiple T2 hyperintense ‘snowball’ lesions in the corpus callosum and periventricular white matter; fluorescein angiography showing multiple branch retinal artery occlusions; CSF with mild pleocytosis and elevated protein but no oligoclonal bands. This combination is classic for Susac syndrome (autoimmune microangiopathy with triad of encephalopathy, BRAO, and sensorineural hearing loss).\\nThe keyed answer (C, Susac Syndrome) is strongly supported and clearly superior to alternatives. Multiple sclerosis could explain white-matter lesions and encephalopathy but would not explain BRAO and the specific callosal ‘snowballs’; MS typically shows callososeptal/periventricular Dawson’s fingers and often oligoclonal bands. CADASIL gives migraine, strokes, and white-matter disease but not BRAO or characteristic callosal snowballs. Primary CNS angiitis can cause multifocal CNS deficits but not the specific triad with BRAO and hearing loss. MELAS presents with stroke-like episodes, lactic acidosis, and mitochondrial features, not BRAO plus these MRI findings.\\nMain medical accuracy issues: None; description of Susac imaging and clinical triad is accurate and contemporary. Minimal fix: Specify sensorineural nature of hearing loss in the stem to mirror classic teaching, but this is not required for item validity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Subacute encephalopathy/confusion, bilateral hearing loss, visual field deficits; MRI with multiple T2 hyperintense ‘snowball’ lesions in the corpus callosum and periventricular white matter; fluorescein angiography showing multiple branch retinal artery occlusions; CSF with mild pleocytosis and elevated protein but no oligoclonal bands. This combination is classic for Susac syndrome (autoimmune microangiopathy with triad of encephalopathy, BRAO, and sensorineural hearing loss).\nThe keyed answer (C, Susac Syndrome) is strongly supported and clearly superior to alternatives. Multiple sclerosis could explain white-matter lesions and encephalopathy but would not explain BRAO and the specific callosal ‘snowballs’; MS typically shows callososeptal/periventricular Dawson’s fingers and often oligoclonal bands. CADASIL gives migraine, strokes, and white-matter disease but not BRAO or characteristic callosal snowballs. Primary CNS angiitis can cause multifocal CNS deficits but not the specific triad with BRAO and hearing loss. MELAS presents with stroke-like episodes, lactic acidosis, and mitochondrial features, not BRAO plus these MRI findings.\nMain medical accuracy issues: None; description of Susac imaging and clinical triad is accurate and contemporary. Minimal fix: Specify sensorineural nature of hearing loss in the stem to mirror classic teaching, but this is not required for item validity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-008", "question": "A 29-year-old male who has sex with men presents with severe proctitis, tenesmus, and rectal bleeding. Rectal swab NAAT is positive for *Chlamydia trachomatis*. He was treated with Doxycycline 100 mg BID for 7 days with no improvement. His partner recently returned from Europe. Which of the following is the most appropriate management?", "options": ["Repeat Doxycycline 100 mg BID for 7 days", "Azithromycin 1 g single dose", "Ceftriaxone 500 mg IM single dose", "Extend Doxycycline 100 mg BID to complete a 21-day course", "Moxifloxacin 400 mg daily for 14 days"], "answer": "D", "answer_index": 3, "explanation": "Severe proctitis in MSM with a positive Chlamydia test should raise suspicion for Lymphogranuloma Venereum (LGV), caused by L1, L2, or L3 serovars. LGV requires a prolonged course of doxycycline (21 days) compared to non-LGV chlamydia (7 days). Standard treatment failure and severe symptoms (bleeding/tenesmus) strongly support a diagnosis of LGV.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: MSM with severe proctitis, tenesmus, rectal bleeding; rectal NAAT positive for Chlamydia trachomatis; lack of response to standard 7-day doxycycline; partner recently in Europe. These features are classic for rectal LGV (L1–L3) rather than uncomplicated chlamydial infection. LGV management requires doxycycline 100 mg BID for 21 days. Thus, option D (extend doxycycline to complete a 21-day course) is the single best answer.\\nAlternative choices: A (repeat 7-day doxy) would just duplicate inadequate therapy; B (single-dose azithromycin) is for uncomplicated chlamydia and not adequate for LGV proctitis; C (ceftriaxone) targets gonorrhea, not LGV; E (moxifloxacin) is not standard LGV therapy and is more relevant to some resistant Mycoplasma genitalium infections.\\nLogical issues: None; stem provides sufficient discriminating details and the options are clearly distinct.\\nMedical accuracy: The pathophysiology and treatment durations for LGV vs non-LGV chlamydia are accurate and align with current STI guidelines.\\nMinimal fix: Option D wording could clarify total duration (\\\"Extend doxycycline to a total 21-day course\\\") to avoid ambiguity whether to add 14 more days vs restart, though this does not affect the correct concept.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: MSM with severe proctitis, tenesmus, rectal bleeding; rectal NAAT positive for Chlamydia trachomatis; lack of response to standard 7-day doxycycline; partner recently in Europe. These features are classic for rectal LGV (L1–L3) rather than uncomplicated chlamydial infection. LGV management requires doxycycline 100 mg BID for 21 days. Thus, option D (extend doxycycline to complete a 21-day course) is the single best answer.\nAlternative choices: A (repeat 7-day doxy) would just duplicate inadequate therapy; B (single-dose azithromycin) is for uncomplicated chlamydia and not adequate for LGV proctitis; C (ceftriaxone) targets gonorrhea, not LGV; E (moxifloxacin) is not standard LGV therapy and is more relevant to some resistant Mycoplasma genitalium infections.\nLogical issues: None; stem provides sufficient discriminating details and the options are clearly distinct.\nMedical accuracy: The pathophysiology and treatment durations for LGV vs non-LGV chlamydia are accurate and align with current STI guidelines.\nMinimal fix: Option D wording could clarify total duration (\"Extend doxycycline to a total 21-day course\") to avoid ambiguity whether to add 14 more days vs restart, though this does not affect the correct concept.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-009", "question": "A 70-year-old man is evaluated for macrocytic anemia (MCV 105), thrombocytopenia, and recurrent inflammation of the ear and nose cartilage. He also has pulmonary infiltrates. Bone marrow biopsy demonstrates hypercellularity with vacuolization of myeloid and erythroid precursor cells. Genetic sequencing identifies a somatic mutation in *UBA1*. What is the diagnosis?", "options": ["Relapsing Polychondritis", "Myelodysplastic Syndrome (MDS)", "VEXAS Syndrome", "Sweet Syndrome", "Granulomatosis with Polyangiitis"], "answer": "C", "answer_index": 2, "explanation": "VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a recently described disorder caused by somatic mutations in *UBA1*. It connects inflammatory features (polychondritis, vasculitis, infiltrates) with hematologic features (macrocytic anemia, vacuoles in marrow precursors). While it mimics relapsing polychondritis, the presence of marrow vacuoles and the *UBA1* mutation defines VEXAS.", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Elderly man; macrocytic anemia and thrombocytopenia; pulmonary infiltrates; recurrent auricular and nasal chondritis; bone marrow hypercellularity with vacuolization of myeloid and erythroid precursors; somatic UBA1 mutation. These together are classic for VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome, a recently described autoinflammatory disease linking myelodysplastic-like marrow changes with systemic inflammation.\\nAlternative choices: Relapsing polychondritis (A) explains chondritis but not the characteristic marrow vacuoles or UBA1 mutation. Myelodysplastic syndrome (B) fits macrocytosis and cytopenias but not the specific UBA1 mutation or systemic cartilaginous inflammation; marrow vacuoles are particularly associated with VEXAS. Sweet syndrome (D) is neutrophilic dermatosis, not supported by skin findings or UBA1 mutation. Granulomatosis with polyangiitis (E) could explain pulmonary involvement but not the specific marrow/genetic findings.\\nMain logical issues: None; stem clearly leads to a single best answer due to explicit UBA1 mutation and vacuolated precursors.\\nMain medical accuracy issues: None significant; description of VEXAS and distractors is accurate and contemporary.\\nMinimal fix: Add explicit sex-chromosome context (e.g., “X-linked late-onset autoinflammatory syndrome”) for teaching emphasis, though not required for validity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Elderly man; macrocytic anemia and thrombocytopenia; pulmonary infiltrates; recurrent auricular and nasal chondritis; bone marrow hypercellularity with vacuolization of myeloid and erythroid precursors; somatic UBA1 mutation. These together are classic for VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome, a recently described autoinflammatory disease linking myelodysplastic-like marrow changes with systemic inflammation.\nAlternative choices: Relapsing polychondritis (A) explains chondritis but not the characteristic marrow vacuoles or UBA1 mutation. Myelodysplastic syndrome (B) fits macrocytosis and cytopenias but not the specific UBA1 mutation or systemic cartilaginous inflammation; marrow vacuoles are particularly associated with VEXAS. Sweet syndrome (D) is neutrophilic dermatosis, not supported by skin findings or UBA1 mutation. Granulomatosis with polyangiitis (E) could explain pulmonary involvement but not the specific marrow/genetic findings.\nMain logical issues: None; stem clearly leads to a single best answer due to explicit UBA1 mutation and vacuolated precursors.\nMain medical accuracy issues: None significant; description of VEXAS and distractors is accurate and contemporary.\nMinimal fix: Add explicit sex-chromosome context (e.g., “X-linked late-onset autoinflammatory syndrome”) for teaching emphasis, though not required for validity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed124", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed124-010", "question": "A 35-year-old female undergoes a cone biopsy for CIN 3. Pathology reveals invasive squamous cell carcinoma with 2 mm depth of invasion and 5 mm horizontal spread. Lymphovascular space invasion (LVSI) is extensively present. Margins are negative. Imaging shows no lymphadenopathy. She desires future fertility. According to NCCN guidelines, what is the recommended management?", "options": ["Simple trachelectomy", "Radical trachelectomy with pelvic lymph node assessment", "Conization with negative margins is sufficient", "Simple hysterectomy", "Pelvic radiation therapy"], "answer": "B", "answer_index": 1, "explanation": "The patient has Stage IA1 cervical cancer (invasion <= 3mm). However, the presence of Lymphovascular Space Invasion (LVSI) significantly increases the risk of lymph node metastasis and recurrence. Therefore, simple excision (cone) or simple trachelectomy/hysterectomy is insufficient. The recommended management for fertility preservation in IA1 with LVSI is radical trachelectomy with pelvic lymph node assessment (sentinel node or dissection).", "generator_model": "gemini-3-pro-preview", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 35-year-old, desires future fertility; cone shows invasive squamous cell carcinoma with 2 mm stromal invasion (≤3 mm) and 5 mm horizontal spread consistent with FIGO IA1; extensive LVSI present; margins negative; no radiologic lymphadenopathy. NCCN guidance: for IA1 without LVSI, conization or simple hysterectomy can suffice; with LVSI, nodal assessment is recommended. For patients desiring fertility, radical trachelectomy with pelvic lymph node assessment is an accepted/standard option.\\nOption analysis: A (simple trachelectomy) is inadequate oncologic surgery in IA1 with LVSI due to need for radical parametrial resection and nodal assessment. C (conization alone) is appropriate only if LVSI absent. D (simple hysterectomy) does not preserve fertility and still lacks nodal assessment, making it inferior in this scenario and inconsistent with her fertility wishes. E (pelvic radiation) is overtreatment and sterilizing for IA1 disease. Thus B uniquely matches evidence-based management and preserves fertility.\\nMain medical accuracy issue(s): Minor—item simplifies staging/management but is aligned with NCCN principles.\\nMinimal fix: Explicitly state “FIGO stage IA1 with LVSI per NCCN” in stem to lock intended staging reference and clarify guideline basis.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 35-year-old, desires future fertility; cone shows invasive squamous cell carcinoma with 2 mm stromal invasion (≤3 mm) and 5 mm horizontal spread consistent with FIGO IA1; extensive LVSI present; margins negative; no radiologic lymphadenopathy. NCCN guidance: for IA1 without LVSI, conization or simple hysterectomy can suffice; with LVSI, nodal assessment is recommended. For patients desiring fertility, radical trachelectomy with pelvic lymph node assessment is an accepted/standard option.\nOption analysis: A (simple trachelectomy) is inadequate oncologic surgery in IA1 with LVSI due to need for radical parametrial resection and nodal assessment. C (conization alone) is appropriate only if LVSI absent. D (simple hysterectomy) does not preserve fertility and still lacks nodal assessment, making it inferior in this scenario and inconsistent with her fertility wishes. E (pelvic radiation) is overtreatment and sterilizing for IA1 disease. Thus B uniquely matches evidence-based management and preserves fertility.\nMain medical accuracy issue(s): Minor—item simplifies staging/management but is aligned with NCCN principles.\nMinimal fix: Explicitly state “FIGO stage IA1 with LVSI per NCCN” in stem to lock intended staging reference and clarify guideline basis.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}]